 |
 |
In its December 2005 issue, The Lancet Neurology, a highly regarded medical journal, published an editorial on Amgen’s halt of clinical trials for infusion delivery of GDNF for Parkinson’s disease. The author recognized a number of issues that trial participants and their supporters have been advocating for during the last year. “The hard way to a Bill of Rights.” (editorial) The Lancet Neurology. December 2005, Vol.4: p.787 You can read excerpts from the article and access the full text from http://www.pdpipeline.org/gdnf_news.htm#subjevtsrights There are still a number of trial participants whose pumps have been kept operational, in hopes that Amgen will reconsider their decision and allow them to receive treatment again under compassionate use provisions. Also see a proposed Bill of Rights for Parkinson's Research Participants - The Parkinson Pipeline Project hopes that acceptance of this statement of principles will help ensure that future trial participants will be treated with "Respect, beneficience, and justice " see: http://www.pdpipeline.org/rights.htm Linda Herman ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn